[go: up one dir, main page]

CL2019001551A1 - Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes - Google Patents

Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes

Info

Publication number
CL2019001551A1
CL2019001551A1 CL2019001551A CL2019001551A CL2019001551A1 CL 2019001551 A1 CL2019001551 A1 CL 2019001551A1 CL 2019001551 A CL2019001551 A CL 2019001551A CL 2019001551 A CL2019001551 A CL 2019001551A CL 2019001551 A1 CL2019001551 A1 CL 2019001551A1
Authority
CL
Chile
Prior art keywords
phenylethylamino
pyrimido
oxazin
compounds
mutant idh1
Prior art date
Application number
CL2019001551A
Other languages
English (en)
Inventor
Renato Alejandro Bauer
Serge Louis Boulet
Timothy Paul Burkholder
Raymond Gilmour
Patric James Hahn
Zoran Rankovic
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2019001551A1 publication Critical patent/CL2019001551A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

UN COMPUESTO, COMO SE DEFINE EN LA PRESENTE, O COMPOSICIÓN FARMACÉUTICA QUE CONTIENE EL COMPUESTO, PARA USAR EN EL TRATAMIENTO DEL CÁNCER MUTANTE DE IDH1 O IDH2.
CL2019001551A 2016-12-16 2019-06-06 Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes CL2019001551A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662435283P 2016-12-16 2016-12-16

Publications (1)

Publication Number Publication Date
CL2019001551A1 true CL2019001551A1 (es) 2019-10-25

Family

ID=60888651

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001551A CL2019001551A1 (es) 2016-12-16 2019-06-06 Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes

Country Status (37)

Country Link
US (3) US11001596B2 (es)
EP (2) EP3763717B1 (es)
JP (1) JP6793836B2 (es)
KR (1) KR102276022B1 (es)
CN (2) CN110072867B (es)
AU (2) AU2017378060B2 (es)
CA (1) CA3045303C (es)
CL (1) CL2019001551A1 (es)
CO (1) CO2019005287A2 (es)
CR (1) CR20190252A (es)
CY (1) CY1123577T1 (es)
DK (1) DK3555105T3 (es)
DO (1) DOP2019000163A (es)
EA (1) EA036112B1 (es)
EC (1) ECSP19042682A (es)
ES (2) ES2941631T3 (es)
HR (1) HRP20201882T1 (es)
HU (1) HUE052067T2 (es)
IL (1) IL267236B (es)
JO (1) JOP20190142B1 (es)
LT (1) LT3555105T (es)
MA (2) MA47399B1 (es)
MD (1) MD3555105T2 (es)
MX (1) MX385562B (es)
MY (1) MY197313A (es)
NZ (1) NZ754115A (es)
PE (1) PE20190977A1 (es)
PH (1) PH12019501328B1 (es)
PL (1) PL3555105T3 (es)
PT (1) PT3555105T (es)
RS (1) RS61108B1 (es)
SA (1) SA519401897B1 (es)
SI (1) SI3555105T1 (es)
TN (1) TN2019000158A1 (es)
UA (1) UA123640C2 (es)
WO (1) WO2018111707A1 (es)
ZA (1) ZA201903125B (es)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10981911B2 (en) 2016-12-16 2021-04-20 Janssen Pharmaceutica Nv Imidazopyrrolopyridine as inhibitors of the JAK family of kinases
US11059823B2 (en) 2016-12-16 2021-07-13 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases
US11066406B2 (en) 2018-06-15 2021-07-20 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases
US12390451B2 (en) 2021-03-11 2025-08-19 Janssen Pharmaceutica Nv Small molecule inhibitor of the JAK family of kinases

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2961793C (en) 2014-09-19 2021-03-16 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
PT3194376T (pt) 2014-09-19 2019-02-04 Forma Therapeutics Inc Derivados da piridin-2(1h)-ona-quinolinona como inibidores da isocitrato-desidrogenase mutante
EP3194375B1 (en) 2014-09-19 2018-11-21 Forma Therapeutics, Inc. Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
ES2706525T3 (es) 2014-09-19 2019-03-29 Forma Therapeutics Inc Derivados de piridinilquinolinona como inhibidores de isocitrato deshidrogenasa mutante
US10294206B2 (en) 2015-04-21 2019-05-21 Forma Tm2, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US10407419B2 (en) 2015-04-21 2019-09-10 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
PL3640251T3 (pl) 2016-10-24 2022-04-11 Astrazeneca Ab Pochodne 6,7,8,9-tetrahydro-3H-pirazolo[4,3-f]izochinoliny przydatne w leczeniu nowotworu złośliwego
EA036112B1 (ru) * 2016-12-16 2020-09-29 Эли Лилли Энд Компани 7-фенилэтиламино-4h-пиримидо[4,5-d][1,3]оксазин-2-оновые соединения в качестве ингибиторов мутантных idh1 и idh2
MY196317A (en) 2017-01-30 2023-03-24 Astrazeneca Ab Estrogen Receptor Modulators
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
WO2019222553A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Inhibiting mutant idh-1
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
CN115038700B (zh) * 2019-11-08 2025-07-25 内尔维亚诺医疗科学公司 偕二取代的杂环化合物及其作为idh抑制剂的用途
WO2021194950A1 (en) 2020-03-23 2021-09-30 Eli Lilly And Company Combination therapy with a mutant idh inhibitor and a bcl-2 inhibitor
AU2021242260B2 (en) * 2020-03-23 2023-12-14 Eli Lilly And Company Combination therapy with a mutant IDH inhibitor
JP7462789B2 (ja) * 2020-03-23 2024-04-05 イーライ リリー アンド カンパニー Ｉｄｈ１阻害剤耐性対象の治療方法
WO2021214253A1 (en) 2020-04-24 2021-10-28 Astrazeneca Ab Dosage regimen for the treatment of cancer
IL297218A (en) 2020-04-24 2022-12-01 Astrazeneca Ab Pharmaceutical formulations
US20230174550A1 (en) * 2020-06-28 2023-06-08 Wigen Biomedicine Technology (shanghai) Co., Ltd. Idh mutant inhibitor and use thereof
US20230255973A1 (en) * 2020-07-20 2023-08-17 Eli Lilly And Company Combination therapy with a mutant idh1 inhibitor, a deoxyadenosine analog, and a platinum agent
CN113588768B (zh) * 2021-05-18 2022-07-05 国家卫生健康委科学技术研究所 一种以分子图像方式定量组织内内源性代谢物的质谱方法
JP2024520854A (ja) 2021-06-09 2024-05-24 イーライ リリー アンド カンパニー Ｉｄｈ阻害剤耐性の対象を治療する方法
US20240208978A1 (en) 2021-06-15 2024-06-27 Wigen Biomedicine Technology (shanghai) Co., Ltd. Idh mutant inhibitor and use thereof
US11746115B2 (en) 2021-08-13 2023-09-05 Eli Lilly And Company Solid forms of 7-[[(1S)-1-[4-[(1S)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one
WO2023141087A1 (en) 2022-01-19 2023-07-27 Eli Lilly And Company Combination therapy with a mutant idh inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013046136A1 (en) * 2011-09-27 2013-04-04 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2014141153A1 (en) * 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2014147586A1 (en) * 2013-03-22 2014-09-25 Novartis Ag 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
US10294206B2 (en) * 2015-04-21 2019-05-21 Forma Tm2, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
CN107405687A (zh) * 2015-04-24 2017-11-28 哈利伯顿能源服务公司 制作陶瓷或金属间化合物零件的方法
US10253041B2 (en) * 2015-07-27 2019-04-09 Eli Lilly And Company 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant IDH1 inhibitors
JP6682043B2 (ja) * 2016-06-06 2020-04-15 イーライ リリー アンド カンパニー 変異体ｉｄｈ１阻害剤
EA036112B1 (ru) * 2016-12-16 2020-09-29 Эли Лилли Энд Компани 7-фенилэтиламино-4h-пиримидо[4,5-d][1,3]оксазин-2-оновые соединения в качестве ингибиторов мутантных idh1 и idh2

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10981911B2 (en) 2016-12-16 2021-04-20 Janssen Pharmaceutica Nv Imidazopyrrolopyridine as inhibitors of the JAK family of kinases
US11059823B2 (en) 2016-12-16 2021-07-13 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases
US11827638B2 (en) 2016-12-16 2023-11-28 Janssen Pharmaceutica Nv Imidazopyrrolopyridine as inhibitors of the JAK family of kinases
US12202831B2 (en) 2016-12-16 2025-01-21 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases
US11066406B2 (en) 2018-06-15 2021-07-20 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases
US11787807B2 (en) 2018-06-15 2023-10-17 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases
US12390451B2 (en) 2021-03-11 2025-08-19 Janssen Pharmaceutica Nv Small molecule inhibitor of the JAK family of kinases

Also Published As

Publication number Publication date
PT3555105T (pt) 2020-12-21
CO2019005287A2 (es) 2019-05-31
AU2020260493B2 (en) 2021-09-09
EP3555105B1 (en) 2020-10-28
EP3763717A1 (en) 2021-01-13
MA47399B1 (fr) 2021-02-26
IL267236B (en) 2020-08-31
UA123640C2 (uk) 2021-05-05
JP6793836B2 (ja) 2020-12-02
AU2020260493A1 (en) 2020-11-26
EA201991161A1 (ru) 2019-11-29
AU2017378060B2 (en) 2020-09-03
PE20190977A1 (es) 2019-07-09
EP3763717B1 (en) 2023-03-08
CN115109075B (zh) 2024-09-20
PH12019501328A1 (en) 2020-02-24
CY1123577T1 (el) 2022-03-24
MA53881A (fr) 2022-04-27
DOP2019000163A (es) 2019-07-15
CA3045303A1 (en) 2018-06-21
US20200079791A1 (en) 2020-03-12
US11001596B2 (en) 2021-05-11
US20210206780A1 (en) 2021-07-08
ES2835281T3 (es) 2021-06-22
NZ754115A (en) 2021-07-30
JOP20190142B1 (ar) 2023-03-28
US11649247B2 (en) 2023-05-16
JOP20190142A1 (ar) 2019-06-13
AU2017378060A1 (en) 2019-05-30
MY197313A (en) 2023-06-13
HRP20201882T1 (hr) 2021-01-22
SA519401897B1 (ar) 2022-07-28
EP3555105A1 (en) 2019-10-23
CN110072867A (zh) 2019-07-30
WO2018111707A1 (en) 2018-06-21
TN2019000158A1 (en) 2020-10-05
MX2019006830A (es) 2019-08-22
KR102276022B1 (ko) 2021-07-13
CN115109075A (zh) 2022-09-27
MX385562B (es) 2025-03-18
ES2941631T3 (es) 2023-05-24
CR20190252A (es) 2019-08-26
BR112019009648A2 (pt) 2019-09-10
HUE052067T2 (hu) 2021-04-28
MA47399A (fr) 2019-10-23
US20210230185A1 (en) 2021-07-29
CA3045303C (en) 2022-05-17
MD3555105T2 (ro) 2021-01-31
LT3555105T (lt) 2021-01-11
ZA201903125B (en) 2024-08-28
ECSP19042682A (es) 2019-06-30
KR20190077539A (ko) 2019-07-03
JP2020502157A (ja) 2020-01-23
PL3555105T3 (pl) 2021-05-17
RS61108B1 (sr) 2020-12-31
US11629156B2 (en) 2023-04-18
IL267236A (en) 2019-08-29
PH12019501328B1 (en) 2023-05-12
EA036112B1 (ru) 2020-09-29
SI3555105T1 (sl) 2020-12-31
DK3555105T3 (da) 2020-11-09
CN110072867B (zh) 2022-07-08

Similar Documents

Publication Publication Date Title
CL2019001551A1 (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
MX2018011992A (es) Compuestos de aminopurina sustituida, composiciones de estos y metodos de tratamiento con estos.
BR112018004620A2 (pt) moduladores da expressão de kras
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
MX2020000386A (es) Inhibidores heterociclicos de la cinasa atr.
EA201891607A1 (ru) Axl-специфичные конъюгаты антитело-лекарственное средство для лечения злокачественных новообразований
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
CR20150571A (es) Compuestos y composiciones terapéuticos
CL2009000483A1 (es) Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer.
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
PH12019502174A1 (en) Modulators of pcsk9 expression
MX2018010993A (es) Derivados de icariina e icaritina.
MX2016010524A (es) Derivados de piridazina para uso en la prevencion o tratamiento de trastorno ataxico.
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
CR20150148A (es) Azaindolinas
MX2017003469A (es) Inhibidores macrociclicos de cinasa rip2.
UY38472A (es) Moduladores de la expresión de foxp3
MX2020003554A (es) Moduladores de la expresion de enac.
CL2015003606A1 (es) Combinación de derivado de imidazopiridazina y un agente mitotico para el tratamiento del cancer